Skip to main content
. 2013 Feb 15;123(3):1262–1274. doi: 10.1172/JCI65268

Figure 1. Increased death and SND in WT diabetic mice after MI.

Figure 1

(A) Survival in WT mice treated with vehicle (Veh) (n = 10), STZ (n = 14), STZ and insulin (n = 7), and MitoTEMPO (Mito) and STZ (n = 11) and in AC3-I (n = 13), MM-VV (n = 19), and Ncf1–/– mice treated with STZ (n = 7) after MI. Overall P = 0.005 by 1-way ANOVA, P < 0.05 for comparisons between WT STZ and all other groups except the Ncf1–/– group (P = 0.7). (B–F) In vivo data from ECG-telemetered WT mice treated with vehicle, STZ, STZ and insulin, and MitoTEMPO and STZ and from AC3-I, MM-VV, and Ncf1–/– mice treated with STZ after MI (n = 4–14 per group). (B) Representative heart rate (HR) tracings ending in death. (C) Representative ECGs. Arrowheads indicate P waves. (D) Resting heart rates. Overall P < 0.0001, *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way ANOVA. (E) Episodes of severe bradycardia (heart rate <200 beats per minute). Overall P = 0.0004, *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way ANOVA. (F) Spontaneous activity-responsive heart rate (ARHR) increase (overall P = 0.001 for activity 1–10, P = 0.0005 for activity level 11–15, P = 0.0002 for all other activity levels by 1-way ANOVA).